Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of PD-1 Antibody Camrelizumab in Combination With Nab-paclitaxel Plus Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

NCT04498689 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT04498689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04498689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of PD-1 Antibody Camrelizumab in Combination With Nab-paclitaxel Plus Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2019
Completion date
December 31, 2022
Enrollment
117 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer